FDA
OrganizationRelationship Network
EFTA00030767.pdf
This document is a Public Policy Law360 email newsletter dated July 20, 2021, summarizing various legal and policy news stories. Crucially, it includes a report that Ghislaine Maxwell owes the New York State Tax Department nearly $1.6 million, identifying her as a former associate of Jeffrey Epstein. Other topics include the confirmation of Tiffany Cunningham as a Federal Circuit judge, a potential $30M fine for Robinhood, and various other legislative and judicial updates.
HOUSE_OVERSIGHT_026763.jpg
This document is a printout of a Forbes article dated September 9, 2017, titled 'Swedish American Group Focuses On Cancer, Autoimmune Diseases At Life Science Summit.' The article details the proceedings of the SALSS conference, highlighting specific biotech companies including AVRA Medical Robotics, SmartwiseSweden AB, and ProLung, along with quotes from their executives. The document bears the stamp 'HOUSE_OVERSIGHT_026763,' indicating it was part of a Congressional investigation, likely related to Jeffrey Epstein's connections to scientific communities or investments, though his name does not appear in the text.
HOUSE_OVERSIGHT_027085.jpg
A single presentation slide titled 'The Product Case for FC2' outlining the market advantages of the FC2 Female Condom. It highlights approvals by the FDA and WHO, procurement by UNFPA and USAID, global distribution to 144 countries, and support provided by the manufacturer, FHC (The Female Health Company). The document bears a House Oversight Bates stamp.
HOUSE_OVERSIGHT_027078.jpg
This document is a promotional or informational slide for The Female Health Company regarding their product, the FC2 female condom. It outlines the product's benefits, including protection against HIV/AIDS, STIs (specifically mentioning Zika), and pregnancy, while noting approvals by the FDA and WHO. The document includes a footer 'HOUSE_OVERSIGHT_027078', indicating it is an exhibit within a House Oversight Committee investigation.
HOUSE_OVERSIGHT_027073.jpg
This document page, stamped with a House Oversight identifier, appears to be a product information sheet or white paper regarding the 'FC2' female condom produced by FHC (The Female Health Company). It details the economic benefits of the product in sub-Saharan Africa, the material advantages of nitrile polymer over latex, and provides statistics from the WHO and UNAIDS regarding the HIV/AIDS epidemic and its specific impact on women. While contained in a batch of documents often associated with investigations involving Jeffrey Epstein or the Clinton Foundation, this specific page focuses entirely on public health data and product specifications.
HOUSE_OVERSIGHT_027072.jpg
This document is a proposal from the Female Health Company (FHC) seeking partnership and funding from new donors to supply FC2 female condoms to African nations (specifically Uganda, Kenya, and Zimbabwe) to combat HIV/AIDS. It highlights a funding gap, offers branding opportunities for donors, and cites economic effectiveness studies by Dr. David Holtgrave of Johns Hopkins to justify the investment. The document appears to be part of a larger House Oversight investigation file (HOUSE_OVERSIGHT_027072), likely related to solicitations made to the Epstein Foundation or related entities.
HOUSE_OVERSIGHT_027071.jpg
This document is a 'Call to Action' fact sheet produced by FHC regarding the FC2 female condom and HIV/AIDS statistics. It highlights the disproportionate impact of HIV on women in Sub-Saharan Africa and argues that funding cuts to UNFPA and USAID under the Trump administration are negatively impacting condom procurement. It includes statistical data on the epidemic and a table showing declining procurement numbers from 2012 to 2016.
HOUSE_OVERSIGHT_024725.jpg
This document is page 89 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It predicts legislative changes in 2018 for various states and analyzes the timeline for federal legalization based on public support data from Gallup. The document bears a 'HOUSE_OVERSIGHT_024725' Bates stamp, indicating it was part of a document production to the House Oversight Committee, though the content itself is a general market analysis rather than specific correspondence.
HOUSE_OVERSIGHT_024724.jpg
This page from an Ackrell Capital investment report outlines three potential regulatory scenarios for the future of cannabis in the United States. It details hypothetical frameworks for the FDA routine approval of CBD and THC drugs, as well as a broader scenario where the federal government fully legalizes cannabis and establishes a new regulatory agency.
HOUSE_OVERSIGHT_024723.jpg
This page from an Ackrell Capital report outlines three key predictions for the U.S. legal landscape regarding cannabis: the FDA approval of cannabis-derived pharmaceuticals involving DEA rescheduling, the expansion and standardization of state medical cannabis laws, and the broader adoption of recreational cannabis laws modeled after alcohol and tobacco regulations.
HOUSE_OVERSIGHT_024722.jpg
This document is page 86 of a December 2017 Cannabis Investment Report by Ackrell Capital. It discusses the regulatory landscape involving the DEA and FDA, specifically highlighting GW Pharmaceuticals' NDA for Epidiolex and providing six predictions regarding the path to federal cannabis legalization in the US. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024721.jpg
This document is page 85 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It discusses the path to federal legalization, analyzing the roles of the DEA and FDA, the conflict between state and federal regulations, and the bureaucratic hurdles stalling the approval of cannabis-derived drugs under the leadership of Attorney General Jeff Sessions. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional oversight committee.
HOUSE_OVERSIGHT_024713.jpg
This document is page 77 of a 2017 report by Ackrell Capital, LLC, discussing the U.S. legal landscape for the cannabis industry. It specifically details the Bank Secrecy Act (BSA), money laundering statutes, and the 2014 FinCEN Memo regarding how financial institutions should handle marijuana-related businesses and file Suspicious Activity Reports (SARs). The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a congressional investigation, though the text itself does not mention Jeffrey Epstein.
HOUSE_OVERSIGHT_024712.jpg
Page 76 of a December 2017 Cannabis Investment Report authored by Ackrell Capital. The text analyzes the regulatory landscape for cannabis-based foods and dietary supplements under the FD&C Act, specifically focusing on FDA and DEA policies regarding THC and CBD. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a congressional document production, though no specific individuals (including Epstein) are named on this page.
HOUSE_OVERSIGHT_024710.jpg
This document is page 74 of a 'Cannabis Investment Report' published by Ackrell Capital in December 2017. It details the regulatory framework for drugs under the FD&C Act, defining what constitutes a drug and outlining the FDA's four-step approval process (from animal testing to New Drug Application). The document bears a 'HOUSE_OVERSIGHT_024710' Bates stamp, indicating it was part of a document production for a Congressional investigation.
HOUSE_OVERSIGHT_024703.jpg
This document is page 67 of a 2017 report by Ackrell Capital titled 'Chapter IV U.S. Legal Landscape.' It analyzes the conflict between U.S. state and federal laws regarding the cannabis industry, detailing regulatory requirements, banking difficulties, and taxation issues. It mentions policy shifts by the DOJ, Treasury, DEA, and FDA up to October 2017. The document bears a 'HOUSE_OVERSIGHT' bates stamp, suggesting it was part of a document production for a congressional investigation, though the page itself contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024692.jpg
This document is page 56 of a December 2017 Cannabis Investment Report produced by Ackrell Capital, LLC. It analyzes risks regarding FDA approval and product liability, outlines the outlook for consumer products (flower, edibles, etc.), and discusses business solutions and software within the cannabis industry. The document bears a 'HOUSE_OVERSIGHT_024692' Bates stamp, indicating it was part of a document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024646.jpg
This page from an Ackrell Capital report discusses the potential first FDA approval of a cannabis-derived pharmaceutical (Epidiolex) in 2018 and its implications. It also analyzes the commoditization of cannabis flower, noting a downward pricing trend in legalized states like Colorado, Oregon, and Washington, illustrated by a graph of prices from 2016 to 2017.
HOUSE_OVERSIGHT_024643.jpg
This document is page 7 of an executive summary by Ackrell Capital regarding the U.S. Legalized Cannabis Market. It contains a chart projecting market growth and consumer numbers from 2016 to 2030. The text focuses on trends to watch in 2018, specifically the impact of recreational legalization in California and Canada. The document bears a 'HOUSE_OVERSIGHT_024643' stamp, but the content is strictly related to cannabis market analysis and contains no mention of Jeffrey Epstein or related associates.
HOUSE_OVERSIGHT_024642.jpg
This page from a 2017 Ackrell Capital investment report outlines a six-step prediction for the federal legalization of cannabis in the United States. It details specific milestones involving the FDA and legislative changes, projecting a timeline where full legalization occurs by 2027, which would serve as a major catalyst for market growth.
HOUSE_OVERSIGHT_024634.jpg
This document is a slide from a 2017 market research presentation by Ackrell Capital, LLC regarding the U.S. Legalized Cannabis Market. It features a chart projecting market growth and consumer numbers through 2030, contingent on federal legalization milestones, and a diagram categorized by industry segments (Production, Business Solutions, Distribution, Digital Media, and Consumer Products). The document bears the Bates stamp HOUSE_OVERSIGHT_024634, indicating it is part of a larger evidence collection.
HOUSE_OVERSIGHT_024051.jpg
This document is a page from a confidential investment memorandum (Control Number 257) produced for the House Oversight Committee. It details the investment strategy for 'NLV-III' (New Leaf Ventures III), focusing on healthcare themes like patient engagement and cost transparency, citing past successes with companies like Audax Health and Truveris. The text outlines the fund's strategy to invest in U.S. private companies, take significant ownership positions, and leverage board participation.
HOUSE_OVERSIGHT_024018.jpg
This document appears to be a page from a confidential investment prospectus for a fund named 'NLV-III' (likely New Leaf Ventures). It outlines the investment strategy, focusing on biopharmaceutical trends such as FDA 'breakthrough therapy' designations and 'information convergence' in healthcare to reduce costs. The document cites a 2013 editorial by FDA Director Janet Woodcock and notes the evolving commercial models of large pharmaceutical companies.
HOUSE_OVERSIGHT_024017.jpg
This document is page 6 of a confidential investment memorandum for New Leaf Ventures III (NLV-III). It outlines the fund's investment strategy, which focuses primarily on the Biopharmaceutical and Information Convergence sectors in the U.S., with a specific emphasis on targeted therapeutics and molecular mechanisms. The document highlights favorable market conditions and a cooperative regulatory environment with the FDA as key drivers for the fund's potential success.
HOUSE_OVERSIGHT_024016.jpg
This document appears to be page 5 of a confidential investment memorandum for a fund named 'NLV-III' (likely New Leaf Ventures III). It outlines the investment thesis, citing a favorable regulatory environment due to increased FDA approvals and the FDASIA act of 2012, as well as favorable capital market dynamics caused by a contraction in venture capital fundraising which reduces competition for deals. The document bears a House Oversight Committee stamp, indicating it was part of a congressional investigation.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity